The Road so Far in Colorectal Cancer Pharmacogenomics: Are We Closer to Individualised Treatment?
Identificadores
Identificadores
URI: http://hdl.handle.net/20.500.11940/16832
PMID: 33228198
DOI: 10.3390/jpm10040237
ISSN: 2075-4426
Visualización o descarga de ficheros
Visualización o descarga de ficheros
Fecha de publicación
2020Título de revista
JOURNAL OF PERSONALIZED MEDICINE
Tipo de contenido
Journal Article
Resumen
In recent decades, survival rates in colorectal cancer have improved greatly due to pharmacological treatment. However, many patients end up developing adverse drug reactions that can be severe or even life threatening, and that affect their quality of life. These remain a limitation, as they may force dose reduction or treatment discontinuation, diminishing treatment efficacy. From candidate gene approaches to genome-wide analysis, pharmacogenomic knowledge has advanced greatly, yet there is still huge and unexploited potential in the use of novel technologies such as next-generation sequencing strategies. This review summarises the road of colorectal cancer pharmacogenomics so far, presents considerations and directions to be taken for further works and discusses the path towards implementation into clinical practice.